Virax Biolabs (VRAX) Finished Goods (2024)
Virax Biolabs (VRAX) posted quarterly Finished Goods of $49404.0 for Q3 2024, down 18.18% quarter-over-quarter from $60383.0 in Q1 2024.
Virax Biolabs (VRAX) Finished Goods (2024) Analysis & Trends
Virax Biolabs' Finished Goods history runs 1 years deep, the most recent figure standing at $49404.0 for Q3 2024.
- In Q3 2024, Finished Goods changed N/A year-over-year to $49404.0; the TTM figure through Sep 2024 stood at $49404.0 (changed N/A YoY), while the FY2024 annual figure was $60383.0, changed N/A from the prior year.
- Finished Goods for Q3 2024 stood at $49404.0, down from $60383.0 in the prior quarter.
- The five-year high for Finished Goods was $60383.0 in Q1 2024, with the low at $49404.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Virax Biolabs | 1.31 Mn | -5.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 49,404.00 |
| Mar 31, 2024 | 60,383.00 |